Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Initial performance of Ga-68-P16-093 in prostate cancer patients including dosimetry and
preliminary efficacy evaluation in BCR patients, and correlation of Ga-68-P16-093 uptake with
tissue histopathology in intermediate to high risk primary prostate cancer patients.